Cite
HARVARD Citation
Rubin, D. et al. (2022). Worldwide post‐marketing safety surveillance experience with tofacitinib in ulcerative colitis. Alimentary pharmacology & therapeutics. 55 (3), pp. 302-310. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Rubin, D. et al. (2022). Worldwide post‐marketing safety surveillance experience with tofacitinib in ulcerative colitis. Alimentary pharmacology & therapeutics. 55 (3), pp. 302-310. [Online].